PharmiWeb.com - Global Pharma News & Resources
15-Jul-2019

Uveitis Treatment Market Size Poised to Touch USD 860 Million by 2026

The Global Uveitis Treatment Market Size projected to register USD 860 Million by 2026, registering at a CAGR growth of 5.5% over the forecast period 2019 to 2026.

The main driver on the market is the increased incidence of uveitis and the associated complications. Furthermore, increased expenses in the studies and development of fresh medicines and treatments as well as innovative biological products are fueling the growth of the industry. In reality, the market has already gained traction in the latest therapy methods for uveitis, like corticasteroids and anti-inflammatory drugs. Additional variables that provide market insight are rapid drug approvals in pipeline and fresh drug administration routes, which enhance drug efficacy.

Although there are many drivers on the market, a number of restrictions can hinder development. Some are high drugs prices and side effects like watery eyes and irritations. Some are very expensive. The absence of awareness of eye disorders, shoddy primary healthcare facilities, and absence of health insurance is also supposed to hinder the market in developing and underdeveloped nations.

Because of the early approval of pipeline medicines in comparison to other areas, North America has been the market leader in uveitis therapy. The increasing incidence of uveitis and associated illnesses, a growing geriatric population, and increased investment in research and development by drug manufacturing firms in the development of new medicines such as corticosteroid products are other factors that lead to growth in the regional economy.

Download Free Sample Report Pages at https://www.acumenresearchandconsulting.com/request-sample/1515

In Europe, the growth in autoimmune illnesses, such as AIDS and various sclerosis, have boosted the uveitis therapy industry. Because of a increasing amount of elderly people and the elevated incidence of eye illnesses, Germany in specific has seen fast development. The Asian market is growing rapidly, too, for the same reasons that markets expand in North America and Europe.

Uveitis, a disease of the autoimmune eye is uncommon for just 38 in 100,000 individuals. It is frequently ignored because of this. After much delay, uveitis patients are often referred to an expert because of their reduced knowledge of eye disease. This delays the diagnosis quickly and leads to irreversible harm of different eye structures.

According to Cochrane, a UK based global Non-Profit, uveitis is the fifth leading cause for sight loss in developed nations. It represents 5% to 20% of blindness, mainly in working individuals. uveitis accounts for 2,4% to 24% of legal blindness in advanced and underdeveloped nations.

Due to the availability of a broad range of alternatives for eye inflammation management in hospitals, hospital pharmacies were the market leader in 2018. In addition, a wide range of patients are treated and cared for in clinics, making hospital doctorates a leading sector. The use of internet pharmacies with a broad variety of medicines and comprehensive product data is anticipated to be important to CAGR throughout the prediction era. Furthermore, an increasing popularity of the e-commerce channels offering discounted prescribed medications is a further driver of development.

Anterior uveitis resulted the market in 2018 as both adults and young people were highly vulnerable. More study in this area also shows that this kind of disease grows with age. The risk of untreated uveitis leading to vision loss as well as cataract growth, glaucoma or retinal oedema is high.

Key Players amp; Strategies

Knowledge of key market participants is increasingly being adopted by key producers such as new product development, mergers and acquisitions, and regional expansion, for example, EyePoint Pharmaceuticals, Inc. was obtained in 2018 by the USA. YUTIQ's FDA approval, a non-infectious uveitis treatment implantable that impacts the back of the eye.

Key players include Bausch amp; Lomb, Inc.; Allergan, Inc.; AbbVie, Inc.; Novartis AG; Eyegate Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd; EyePoint Pharmaceuticals, Inc.

View Detail Information at https://www.acumenresearchandconsulting.com/uveitis-treatment-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Uveitis Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Uveitis Treatment Market By Treatment Type
1.2.2.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison By Treatment Type (2015-2026)
1.2.2.2. Global Uveitis Treatment Market Revenue Share By Treatment Type in 2017
1.2.2.3. Monoclonal Antibodies
1.2.2.4. Cycloplegic Agents
1.2.2.5. Corticosteroids
1.2.2.6. Immunosuppressant
1.2.2.7. Antibiotics
1.2.2.8. Antifungal
1.2.2.9. Antivirals
1.2.2.10. Analgesics
1.2.3. Uveitis Treatment Market By Disease Type
1.2.3.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison By Disease Type (2015-2026)
1.2.3.2. Intermediate Uveitis
1.2.3.3. Posterior Uveitis
1.2.3.4. Anterior Uveitis
1.2.3.5. Panuveitis
1.2.4. Uveitis Treatment Market By Cause
1.2.4.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison By Cause (2015-2026)
1.2.4.2. Noninfectious
1.2.4.3. Infectious
1.2.5. Uveitis Treatment Market By Distribution Channel
1.2.5.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.5.2. Retail
1.2.5.3. Hospital
1.2.5.4. Online
1.2.6. Uveitis Treatment Market by Geography
1.2.6.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Uveitis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Uveitis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Uveitis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Uveitis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Uveitis Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Uveitis Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Uveitis Treatment Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Type of Global Uveitis Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Uveitis Treatment Major Manufacturers in 2017

CHAPTER 4. UVEITIS TREATMENT MARKET BY TREATMENT TYPE

4.1. Global Uveitis Treatment Revenue By Treatment Type
4.2. Monoclonal Antibodies
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Cycloplegic Agents
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Corticosteroids
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Immunosuppressant
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Antibiotics
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Antifungal
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.8. Antivirals
4.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.9. Analgesics
4.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. UVEITIS TREATMENT MARKET BY DISEASE TYPE

5.1. Global Uveitis Treatment Revenue By Disease Type
5.2. Intermediate Uveitis
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Posterior Uveitis
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Anterior Uveitis
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Panuveitis
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. UVEITIS TREATMENT MARKET BY CAUSE

6.1. Global Uveitis Treatment Revenue By Cause
6.2. Noninfectious
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Infectious
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. UVEITIS TREATMENT MARKET BY DISTRIBUTION CHANNEL

7.1. Global Uveitis Treatment Revenue By Distribution Channel
7.2. Retail
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Hospital
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Online
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. NORTH AMERICA UVEITIS TREATMENT MARKET BY COUNTRY

8.1. North America Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Uveitis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. U.S.
8.3.1. U.S. Uveitis Treatment Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
8.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
8.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
8.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 9. EUROPE UVEITIS TREATMENT MARKET BY COUNTRY

9.1. Europe Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Uveitis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.6.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.7.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 10. ASIA-PACIFIC UVEITIS TREATMENT MARKET BY COUNTRY

10.1. Asia-Pacific Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Uveitis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.6.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.6.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.7.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.7.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.8.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.8.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 11. LATIN AMERICA UVEITIS TREATMENT MARKET BY COUNTRY

11.1. Latin America Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Uveitis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
11.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
11.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
11.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 12. MIDDLE EAST UVEITIS TREATMENT MARKET BY COUNTRY

12.1. Middle East Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Uveitis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
12.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
12.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
12.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 13. AFRICA UVEITIS TREATMENT MARKET BY COUNTRY

13.1. Africa Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Uveitis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
13.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
13.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
13.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
13.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
13.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
13.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. Bausch amp; Lomb, Inc.
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Type Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Allergan, Inc.
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Type Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. AbbVie, Inc.
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Type Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Novartis AG
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Type Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Eyegate Pharmaceuticals, Inc.
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Type Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Santen Pharmaceutical Co., Ltd
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Type Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. EyePoint Pharmaceuticals, Inc
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Type Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Others
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Type Portfolio
14.8.5. Key Developments
14.8.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

Request for Customization at https://www.acumenresearchandconsulting.com/request-customization/1515

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1515

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 15-Jul-2019